RxDoctor Payments Data

Shakir Hussein, MD

Transplant Surgery · Detroit, MINPI 1609066455

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 23 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Mallinckrodt Hospital Products Inc. at 24.2% of the total. 2025 is the largest year on record at $335, 2.8 times the $118 reported in 2019.

$953in general payments, 2019–2025

Across 23 payments — averaging $41.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mallinckrodt Hospital Products Inc.$230
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$126
  • E.r. Squibb & Sons, L.L.C.$118
  • Sanofi-aventis U.S. LLC$117
  • Veloxis Pharmaceuticals, Inc.$85
  • Merck$69
  • plus $207 from 7 others

What the payments were for

  • Food & beverage$953100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few transplant surgery providers in Michiganto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$43,770
Medicare patients
36
Services billed
86

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Mycophenolic AcidMycophenolate Sodium34$27,403
Tacrolimus26$17,366
Valganciclovir Hcl55$15,052
Novolog FlexpenInsulin Aspart38$6,019
Ultra-Fine Short Pen NeedlePen Needle, Diabetic42$2,595
Prednisone224$1,605
Midodrine Hcl12$994
Tamsulosin Hcl96$862
Potassium Chloride20$460
Torsemide38$437
Carvedilol42$343
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim58$241
Hydralazine Hcl23$234
Amlodipine Besylate37$215
Clonidine Hcl57$213

Paid to pharmacies, not to this prescriber.

Other transplant surgery in Detroit

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →